Belzupacap sarotalocan is a Recombinant Protein owned by Aura Biosciences, and is involved in 6 clinical trials, of which 1 was completed, 3 are ongoing, and 2 are planned.
AU-011 acts by generating a target protein in a sustained manner for long periods of time. It utilizes an HPV VLP to deliver a cell-killing laser-activated molecule selectively to cancer cells in the eye.
The revenue for Belzupacap sarotalocan is expected to reach a total of $266m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Belzupacap sarotalocan NPV Report.
Belzupacap sarotalocan is originated and owned by Aura Biosciences.
Belzupacap sarotalocan Overview
AU-011 is under development for the treatment of ocular melanoma (melanomas of the iris and the ciliary body), uveal and choroidal melanoma. It is administered as an intravitreal, suprachoroidal, intratumoral and intramural route. The therapeutic candidate is developed based on Nanosmart technology. The drug candidate is a VDC (virus like drug conjugate).
Aura Biosciences Overview
Aura Biosciences is working on a novel class of oncology targeted therapeutics that will provide considerable therapeutic benefit to a variety of cancer indications with a high unmet need. The company is headquartered in United States.
The operating loss of the company was US$35.3 million in FY2021, compared to an operating loss of US$22.2 million in FY2020. The net loss of the company was US$35.3 million in FY2021, compared to a net loss of US$22.2 million in FY2020.
Quick View – Belzupacap sarotalocan
|Highest Development Stage|